Creon
NDC Package 17856-1206-1
Package Information
Creon is this medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. Marketed by Atlantic Biologicals Corps, this product is identified by NDC 17856-1206 and is authorized under FDA application NDA020725.
Identification & Billing
- RxCUI: 855499 - lipase 6000 UNT / amylase 30,000 UNT / protease 19,000 UNT Delayed Release Oral Capsule
- RxCUI: 855499 - amylase 30000 UNT / lipase 6000 UNT / protease 19000 UNT Delayed Release Oral Capsule
- RxCUI: 855499 - amylase 30,000 UNT / lipase 6000 UNT / protease 19,000 UNT Delayed Release Oral Capsule
- RxCUI: 855499 - amylases 30,000 UNT / endopeptidases 19,000 UNT / lipase 6000 UNT Delayed Release Oral Capsule
- RxCUI: 863836 - CREON 6000 UNT / 30,000 UNT / 19,000 UNT Delayed Release Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 17856 - Atlantic Biologicals Corps
- 17856-1206 - Creon
- 17856-1206-1 - 1 CAPSULE, DELAYED RELEASE PELLETS in 1 POUCH
- 17856-1206 - Creon
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 17856-1206-1 identifies a specific commercial package of 1 capsule, delayed release pellets in 1 pouch of Creon, labeled by Atlantic Biologicals Corps. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Atlantic Biologicals Corps on August 13, 2010. The current certification is valid through December 31, 2018.
What are the primary indications for this medication?
This medication contains digestive enzymes to help break down and digest fats, starch, and proteins in food. It is used in conditions where the pancreas cannot make or does not release enough digestive enzymes into the small intestines to digest the food (conditions such as chronic pancreatitis, cystic fibrosis, cancer of the pancreas, post-pancreatectomy, post-gastrointestinal bypass surgery).
How is this Atlantic Biologicals Corps product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 17856120601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.